OpenAI announced on 20 October 2026 that it has acquired Orchestra Bio, a startup whose AI agents help pharmaceutical teams keep drug programmes on schedule. The team and technology join Rosalind, OpenAI's life-sciences unit. Financial terms were not disclosed, and there is no date for when Orchestra's agents will reach OpenAI products.
OpenAI points to the length of drug development, which it says averages 10 to 15 years in the US. Orchestra's agents track studies, finances and clinical-trial scheduling problems. In OpenAI's example, a failed manufacturing batch threatens a trial: the agents work out which timelines are hit and weigh responses, while people make the final call.
Orchestra was founded in San Francisco in 2022 by CEO Ashoka Rajendra and launched in August 2025 with $20 million from Andreessen Horowitz, 8VC, Insight Venture Management and others. GPT-Rosalind arrived in April as a biology and drug-discovery reasoning model and has been open to eligible organisations beyond the research preview since September. Novo Nordisk and Moderna already work with OpenAI on it.
The deal follows OpenAI's January purchase of Torch Health for ChatGPT Health, and Anthropic's roughly $400 million acquisition of Coefficient Bio in April.
Sources · 2